Ozempic or Wegovy: which one leads to more weight loss?

You've seen both names everywhere, here's why they're not the same thing

Picture this: you're doing your research late in the evening, you've seen Ozempic mentioned on a morning show, Wegovy cropping up in a broadsheet article, and now you're wondering whether you'd do better on one or the other. It's a reasonable question. But the framing slightly misses the mark, and understanding why is actually useful.

Both medicines are semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite and influences the brain's satiety signalling. The molecule is identical. What differs is the licensed indication and, critically, the dose ceiling. Ozempic was developed and licensed for blood sugar control in adults with type 2 diabetes; its approved doses in the UK top out at 1mg or 2mg weekly. Wegovy was developed specifically for weight management and is licensed at doses up to 2.4mg, and, since April 2026, up to 7.2mg for suitable patients. If you want a thorough look at how Ozempic and Wegovy compare for weight loss, including what the dose differences mean in practice, we've covered that in full. You can also read more about how semaglutide works across both products on our Ozempic vs semaglutide explainer.

That dose difference is not cosmetic. Semaglutide's weight-loss effect is dose-dependent: as the weekly dose rises, appetite suppression deepens. Licensing the medicine at a higher dose for weight management is precisely why Novo Nordisk developed Wegovy as a separate product rather than simply pointing patients towards Ozempic. They are, in regulatory terms, different medicines with different approvals.

What the trial numbers actually show

The STEP 1 trial (68 weeks, adults with obesity or overweight plus at least one weight-related condition, semaglutide 2.4mg weekly) found an average body weight reduction of around 15%, as reported in the New England Journal of Medicine. Participants who stayed fully adherent to the protocol did better still.

Diabetes trials with Ozempic at 1mg weekly showed average weight reductions typically in the 4–6% range, though those studies were designed around HbA1c targets rather than weight, so direct comparison is imperfect. The point stands: when you ask whether you lose more weight on Ozempic or Wegovy, the honest answer is Wegovy (by a considerable margin at the licensed doses) and that gap grows further with the newer 7.2mg pen, which the MHRA approved on 14 April 2026 and which produced around 20.7% average weight loss in trials.

If you're weighing up how Wegovy sits against Mounjaro (tirzepatide), which works on two receptors rather than one, our Wegovy comparison pages cover that in detail. The short version is that Mounjaro produced greater average weight loss than semaglutide 2.4mg in the SURMOUNT-5 head-to-head trial, though the 7.2mg Wegovy dose narrows the gap meaningfully.

What's actually licensed for weight loss in the UK, and what that means for you

The MHRA licenses medicines for specific indications, and that matters. Ozempic is licensed for type 2 diabetes. It is not licensed for weight management. A UK prescriber offering semaglutide for weight loss is prescribing Wegovy, full stop. The NHS medicines information on semaglutide sets this out clearly: the two brand names exist because they serve different patient populations, at different doses, under different NICE appraisals.

NICE has recommended Wegovy for weight management under TA875, with eligibility linked to BMI thresholds and the presence of at least one weight-related condition. NICE has not recommended Ozempic for weight management because Ozempic is not submitted for that purpose. Anyone selling Ozempic as a weight-loss treatment without that clinical framing (particularly at prices that seem too good to be true) should raise immediate concern. The MHRA has warned publicly about counterfeit and illicitly traded semaglutide pens; if a seller is offering what they describe as Ozempic for slimming, that is a significant red flag.

Wegovy costs vary by dose and provider; you'll find an honest breakdown of what the market looks like on our Wegovy cost page. For context on how the two brand names compare in practice, our Wegovy vs Ozempic page goes through the key differences side by side.

If your goal is weight loss, here's where to focus your attention

The practical upshot is straightforward. If you have type 2 diabetes and your GP prescribes Ozempic, that is the right medicine for you and weight loss may be a welcome side effect. If your primary goal is weight management, the medicine to ask about is Wegovy, or, depending on your clinical picture, Mounjaro.

Both Wegovy and Mounjaro are available as private prescriptions through regulated UK pharmacies for people who meet the eligibility criteria. You do not need a GP referral for the private route. You do need a genuine clinical assessment (BMI, medical history, current medicines, a verification of your identity and weight) conducted by a real prescriber before anything is dispensed. Our clinical team works through every consultation the same day it's submitted; nothing is automated. That matters more than most people realise when they're comparing options from a search results page at midnight.

A quick practical note: the 12pm cut-off for same-day dispatch means many patients who complete their consultation in the morning have their treatment on the way before lunch. Getting that process started is the right next step once you've done the research.

If you'd like to explore whether Wegovy or Mounjaro suits your situation, take a look at our weight-loss treatment overview or check whether you might be switching from Ozempic to Wegovy under prescriber guidance. When you're ready, speak to our prescribers through a free consultation and get a same-day clinical review.